Lp(a): What This Test Actually Measures
Lipoprotein(a), abbreviated Lp(a) and sometimes written "LP little a," is a distinct lipoprotein particle, not a subtype of LDL cholesterol and not the same thing as the "lipid panel" most people get at an annual physical. It consists of an LDL-like core attached to a protein called apolipoprotein(a). The Lp(a) blood test measures the concentration of this particle directly, using an assay separate from the standard cholesterol panel.
This article is a draft prepared for clinician and editorial review. It has not yet completed medical review, and specific numeric claims below are flagged where independent verification against the primary literature is still needed.
The core answer
Lp(a) concentration is influenced heavily by inherited variation in the LPA gene, and levels are relatively stable across adult life compared with LDL cholesterol or triglycerides, which is why many guideline bodies suggest measuring it once rather than repeatedly. Elevated Lp(a) is treated by cardiology guideline groups as a marker that adds information beyond a standard lipid panel, but as of this writing there is no FDA-approved drug that lowers Lp(a) specifically, so a high result changes how aggressively other risk factors (LDL-C, blood pressure, smoking) are managed rather than triggering a Lp(a)-targeted prescription. Readers should treat single-source percentage figures for risk multipliers or drug effect sizes in older summaries with caution until checked against the current primary literature.
What Lp(a) is and why it is not just "another LDL number"
Lp(a) is an LDL-like particle bound to apolipoprotein(a), a protein structurally related to plasminogen. Because of this structure, researchers have proposed that Lp(a) can act through two separate pathways: contributing to plaque buildup in arteries (similar to LDL) and interfering with normal clot-dissolving activity (a property LDL does not have). A general reference on Lp(a) as a cardiovascular risk marker and as a target for apheresis therapy describes this dual biology and its role in guiding both risk assessment and, in refractory cases, physical removal of the particle from blood (Lipoprotein(a): marker for cardiovascular risk and target for lipoprotein apheresis).
A standard lipid panel does not isolate Lp(a). The cholesterol carried inside Lp(a) particles is folded into your reported LDL-C number. Two people with an identical LDL-C on a basic panel can have meaningfully different Lp(a) burdens, and the basic panel cannot tell them apart. That is the practical reason a separate Lp(a) test exists.
Genetic studies generally describe Lp(a) concentration as substantially heritable, with the LPA gene locus accounting for most of the variation between individuals. The exact percentage attributed to genetics varies by study population and methodology; readers should treat any single precise figure (for example, "80-90%") as an approximation pending confirmation from a specific cited study, not a fixed biological constant.
How the lab actually measures it
Most clinical laboratories use immunoassay methods (immunoturbidimetric or immunonephelometric) that detect apolipoprotein(a). A venous blood draw is used, and fasting is generally not required, since Lp(a) does not appear to shift meaningfully with recent food intake the way triglycerides do. Confirm your specific lab's fasting instructions rather than assuming.
Two reporting units exist: mg/dL (a mass measurement) and nmol/L (a molar, particle-count measurement). These are not interchangeable through a simple multiplication factor. The reason is a structural quirk of apolipoprotein(a): it contains a variable number of repeating protein segments called kringle IV type 2 (KIV-2) domains, and this repeat number differs from person to person. Mass-based assays are sensitive to this size variation in a way that can distort results at both ends of the range. Several guideline and consensus groups have therefore pushed laboratories toward molar reporting using isoform-insensitive assays. If your report is in mg/dL and you want an nmol/L equivalent, ask the ordering clinician or lab rather than applying a rule-of-thumb conversion, particularly if your result is unusually high or low.
Decision framework: should you order this test, and what should the result change?
Use this as a starting checklist for a conversation with a clinician, not as a substitute for one.
| Situation | What the evidence suggests | Reasonable next step |
|---|---|---|
| You have no personal or family history of early heart disease and no prior lipid testing | Guideline groups (e.g., EAS) generally support a one-time Lp(a) check somewhere in adulthood to establish a lifelong baseline | Ask whether a baseline Lp(a) makes sense at your next lipid panel; this is a discussion, not a self-order decision |
| You or a close relative had a heart attack, stroke, or aortic valve disease before the usual age for it | Elevated Lp(a) is more prevalent in early-onset cardiovascular disease cohorts | Testing is more clearly indicated here; discuss with your clinician |
| You already know your Lp(a) is elevated and it was measured more than once in adulthood without an intervening illness | Because the level is thought to be largely fixed genetically, repeat testing usually adds little | Generally no need to recheck unless starting a PCSK9 inhibitor, joining a trial, or the first test was done during acute illness or pregnancy |
| Your Lp(a) came back elevated | There is currently no FDA-approved Lp(a)-lowering drug | The clinically actionable response is tightening control of LDL-C, blood pressure, glucose, and smoking status, not waiting for an Lp(a)-specific pill |
| Your Lp(a) came back low | No known adverse consequence is associated with low Lp(a) | No action needed |
| A first-degree relative has known elevated Lp(a) | Inheritance patterns suggest roughly even odds of a child inheriting a high-Lp(a) allele from an affected parent, though exact figures depend on the specific variant | Cascade testing of close relatives is reasonable to discuss, ideally through a clinician familiar with lipid genetics |
Normal ranges and how thresholds are used
Guideline bodies, including the European Atherosclerosis Society, have proposed thresholds along the lines of: desirable below roughly 30 mg/dL (about 75 nmol/L), borderline in the 30-50 mg/dL range, and elevated above roughly 50 mg/dL (about 125 nmol/L). Different professional societies (European, Canadian, and US lipid groups) do not use perfectly identical cutpoints, and units matter, so a specific number should be interpreted using the reference range and units printed on your own lab report, not a number from an article.
Median Lp(a) levels differ across ancestral populations, with several studies reporting higher median levels in individuals of Black African and South Asian ancestry compared with individuals of European ancestry. The degree of difference reported varies by study and should not be treated as a precise multiplier without checking the specific source.
What elevated Lp(a) is associated with
Observational cohort studies and Mendelian randomization analyses (a genetic method used to test whether an association is likely causal) have linked higher Lp(a) with increased risk of coronary heart disease, ischemic stroke, peripheral artery disease, and calcific aortic valve stenosis. The general direction of this evidence, association with cardiovascular events, is well established across multiple independent research groups. The precise magnitude of added risk (specific fold-increases or hazard ratios cited in older summaries) should be verified against the original trial or cohort publication before being repeated as a firm number, since figures are frequently misquoted or attached to the wrong source in secondary write-ups.
Because standard statin therapy lowers LDL-C but does not reliably lower Lp(a), a person who reaches an on-treatment LDL-C goal can still carry residual cardiovascular risk attributable to Lp(a). This is a genuinely important nuance: "LDL at goal" is not the same as "Lp(a)-related risk addressed."
What a low result means
A low Lp(a) has no known adverse health implication. It reflects a favorable combination of inherited LPA variants, not an achievement to be maintained through lifestyle, and there is no established clinical rationale for trying to raise Lp(a). Certain acute conditions (active inflammation, nephrotic syndrome, liver dysfunction, pregnancy) can transiently shift measured Lp(a) in either direction; a level checked during acute illness should generally be rechecked once the acute condition resolves before it is used for long-term risk planning.
Current and investigational treatment landscape
As of this writing, no drug is FDA-approved specifically to lower Lp(a). Several existing lipid drugs (PCSK9 inhibitors, niacin) have been reported to reduce Lp(a) to a modest degree as a secondary effect, but niacin in particular failed to show cardiovascular outcome benefit in large outcome trials despite lowering Lp(a) and other lipid markers, an important caution against assuming that lowering the number automatically lowers cardiovascular events.
Lipoprotein apheresis, a procedure that mechanically filters Lp(a) and other lipoproteins from blood, is used in a small number of specialized centers for patients with very high Lp(a) and progressive cardiovascular disease despite other therapy. A 2026 trial (Lp(a)FRONTIERS APHERESIS) is evaluating apheresis alongside the investigational drug pelacarsen in secondary prevention, reflecting active research interest in whether physically removing Lp(a) changes outcomes (Pelacarsen and lipoprotein(a) apheresis in secondary prevention). This is trial-stage evidence, not an approved treatment pathway, and results should not be assumed until the trial reports.
Several antisense and siRNA drugs targeting Lp(a) production (including agents sometimes referred to by names such as pelacarsen, olpasiran, and lepodisiran in the research literature) are in various stages of clinical trials and have been reported to substantially lower circulating Lp(a) in early-phase studies. Whether that reduction translates into fewer heart attacks, strokes, or valve interventions is the question the ongoing outcome trials are designed to answer, and it is not yet established. Readers should not interpret a large percentage reduction in Lp(a) concentration as proof of a corresponding reduction in cardiovascular events until outcome trial results are published and reviewed.
Managing an elevated result today
Because no Lp(a)-specific therapy is approved, clinical management of an elevated result generally focuses on the risk factors that can be modified:
- Aggressive LDL-C lowering toward goals set by your clinician
- Blood pressure control
- Diabetes control if applicable
- Smoking cessation
- Consideration of a PCSK9 inhibitor if LDL-C remains above goal on maximally tolerated statin therapy, a decision that belongs to your prescribing clinician
- Discussion of cascade testing for first-degree relatives
Diet, exercise, and weight loss are not established methods of lowering Lp(a) concentration itself, even though they remain important for overall cardiovascular risk and for the LDL-C, blood pressure, and glucose factors that are modifiable. Framing an elevated Lp(a) as a personal failure of lifestyle is not supported by the evidence and is not a useful way to talk with patients about it.
Repeat testing: when it does and does not make sense
Because Lp(a) concentration is thought to be set largely by inherited factors and to change little across adult life, most guideline statements describe serial monitoring as adding little value in a person with no new clinical reason to recheck. Reasonable exceptions include after starting a PCSK9 inhibitor (to see the degree of change), enrollment in a trial of an Lp(a)-lowering drug, or if the original test was drawn during acute illness, a nephrotic flare, or pregnancy. Routine annual rechecking, or rechecking after a diet change, is not generally supported by the evidence on Lp(a) biology.
Evidence boundary: what is established, what is not
Reasonably well established: Lp(a) is a distinct, largely inherited lipoprotein not captured by a standard lipid panel; higher Lp(a) is associated with increased cardiovascular and aortic valve disease risk across multiple independent cohorts; statins do not meaningfully lower Lp(a) and may modestly raise it; there is currently no FDA-approved Lp(a)-lowering drug.
Plausible but not settled: the exact magnitude of risk conferred at specific Lp(a) thresholds, the degree to which lowering Lp(a) pharmacologically will reduce cardiovascular events (this is the specific question current outcome trials are testing), and whether isoform-insensitive molar assays meaningfully change clinical decisions compared with mass-based assays in typical practice.
Not established: that any current supplement, diet, or exercise regimen lowers Lp(a) concentration; that lowering Lp(a) with an investigational drug reduces heart attacks or strokes (pending outcome trial results); precise ancestry-based multipliers or risk ratios cited without a verified source.
When to seek urgent care
An elevated Lp(a) result is not an emergency and does not require same-day evaluation on its own. Chest pain, sudden weakness or numbness, slurred speech, or other symptoms suggestive of a heart attack or stroke warrant emergency care regardless of your lab results.
Frequently asked questions
What is a normal Lp(a) level?
What does a high Lp(a) mean?
What does a low Lp(a) mean?
Can diet or exercise lower Lp(a)?
Do statins lower Lp(a)?
How often should Lp(a) be measured?
Is Lp(a) included in a standard lipid panel?
What medications can lower Lp(a)?
Should my children be tested for Lp(a)?
Can Lp(a) cause aortic valve stenosis?
References
- Kronenberg F, et al. Lipoprotein(a): marker for cardiovascular risk and target for lipoprotein apheresis. https://pubmed.ncbi.nlm.nih.gov/31818445/
- Lp(a)FRONTIERS APHERESIS trial. Pelacarsen and lipoprotein(a) apheresis in secondary prevention (2026). https://pubmed.ncbi.nlm.nih.gov/41721795/
Numeric figures for specific risk ratios, effect sizes, and percentage reductions referenced in earlier drafts of this article require verification against their original primary sources before publication. This version intentionally omits precise citations that could not be confirmed and should be treated as a draft pending clinical and editorial review.